SAPROPTERIN DIHYDROCHLORIDE — HIKMA, approved 2025-06-11 (ANDA218797).
3,607 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.